HC Wainwright restated their buy rating on shares of Aethlon Medical (NASDAQ:AEMD – Free Report) in a research report released on Friday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the medical equipment provider’s stock.
Separately, StockNews.com initiated coverage on shares of Aethlon Medical in a report on Friday, November 8th. They set a “sell” rating on the stock.
Check Out Our Latest Analysis on Aethlon Medical
Aethlon Medical Trading Up 0.2 %
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Read More
- Five stocks we like better than Aethlon Medical
- Retail Stocks Investing, Explained
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- How to Capture the Benefits of Dividend Increases
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.